Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splenopein oral solution plus conventional postoperative therapy for chronic rhinosinusitis with nasal polyps
ChiCTR2200059420Phase 4Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Jul 2021
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of splenopein in chronic rhinosinusitis with nasal polyps (CRSwNP) and allergic rhinitis (AR) (2 arms), sponsored by Beijing Tongren Hospital. Primary endpoint: Total clinical response rate at 24 weeks. Started Jul 2021; status: completed.
02
Drugs
splenopein
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR2200059420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059420.